Everest Medicines Ltd. has announced positive results from its ongoing Phase 1b/2a clinical trial for EVER001, a next-generation covalent reversible Bruton's tyrosine kinase $(BTK.AU)$ inhibitor, aimed at treating primary membranous nephropathy (pMN) and other autoimmune renal diseases. The results were presented in a focused oral session at the 62nd Congress of the European Renal Association (ERA 2025). EVER001 was found to be generally safe and well tolerated, with no clinically significant adverse events typically linked to covalent irreversible BTK inhibitors, such as bleeding or severe liver function impairment. This trial marks a significant step as there is currently no globally approved drug for pMN, and EVER001 has the potential to provide new treatment options for over 10 million patients worldwide. The company plans to continue the global clinical development of EVER001.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。